Selected Translational Opportunities
CellMedics is developing BIOAVAILANT® across therapeutic areas where non-invasive local, transdermal, ocular, or systemic delivery of biologics and other hard-to-deliver macromolecules may offer significant scientific, clinical, and commercial value. The platform is being positioned for applications in which conventional administration depends heavily on injections, infusions, or device-assisted delivery.
Immuno-Oncology and Skin-Directed Immunotherapy
BIOAVAILANT® is being evaluated for localized delivery of checkpoint inhibitors and other immunomodulatory agents into skin and tumor-adjacent tissues.
• Ex vivo human skin data with a PD-1 checkpoint inhibitor support delivery into epidermal and dermal compartments.
• Localized skin delivery may support therapeutic exposure at the site of disease while potentially reducing the burden associated with systemic administration.
• This application area is relevant to dermatologic oncology, field-directed immunotherapy, and other skin-localized immune-mediated conditions.
Dermatology and Skin-Directed Therapeutics
BIOAVAILANT® is designed to support topical and transdermal delivery of larger and more complex therapeutic molecules that are difficult to deliver using conventional topical systems.
• Potential applications include inflammatory skin disorders, immune-mediated dermatology, wound-related indications, and localized biologic delivery.
• The platform may enable differentiated formulations for molecules that otherwise require injection or are unsuitable for standard topical delivery.
Metabolic Disease and Systemic Peptide Delivery
Preclinical studies with a GLP-1 therapeutic candidate support the feasibility of systemic exposure following topical/transdermal administration using BIOAVAILANT®.
• This application area is relevant to obesity, diabetes, and broader cardiometabolic disease settings where peptide and protein therapeutics are commonly administered by injection.
• A needle-free delivery approach may offer a differentiated strategy for selected metabolic therapeutics where patient convenience, adherence, and extended absorption profiles are important.
Musculoskeletal and Inflammatory Disorders
BIOAVAILANT® has demonstrated local tissue bioavailability in a pharmaceutical co-development program involving an approximately 10 kDa biologic.
• Human microdialysis data demonstrated approximately 39% absolute bioavailability in a targeted joint-space environment.
• These findings support the platform’s potential for local delivery in musculoskeletal and inflammatory disorders where high local exposure may be desirable.
Ophthalmic and Ocular Delivery
BIOAVAILANT® is also being positioned for ocular delivery applications involving biologics, peptides, and other difficult-to-deliver molecules.
• Ocular delivery remains a major challenge for larger therapeutic molecules due to tissue barriers, stability constraints, and limitations of conventional administration.
• The platform may support differentiated approaches for selected ophthalmic indications where topical or localized delivery could provide therapeutic and commercial value.
Platform Development Perspective
CellMedics is prioritizing applications where BIOAVAILANT® can provide clear differentiation over conventional injection, infusion, or device-assisted delivery.
• Near-term partnering opportunities may include feasibility studies with selected therapeutic candidates in oncology, dermatology, metabolic disease, ophthalmology, and inflammatory disorders.
• The platform is intended to support both proprietary CellMedics programs and external pharmaceutical partnering opportunities.
Broad Translational Potential
Collectively, these application areas reflect the breadth of BIOAVAILANT® as a non-invasive delivery platform for biologics and macromolecules. CellMedics is focused on advancing selected opportunities where the platform may enable meaningful improvements in delivery route, tissue targeting, patient convenience, and therapeutic differentiation.